Clinical Trial Update: Cross-Over Study to Assess the Cardiovascular Effects of GSK2336805 [Phase 1]

View source ↗

Summary

This update notes the completion of a Phase 1 cross-over trial evaluating the cardiovascular effects of the hepatitis C investigational drug GSK2336805.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• GSK2336805

Snippet

Sponsor: GlaxoSmithKline | Conditions: Hepatitis C | Phase 1 | Status: COMPLETED